Stockhub

Shield Therapeutics plc: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

15 August 2022

  • curprev 11:5411:54, 15 August 2022 >Paris 694 bytes +694 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal stud..."
Retrieved from "https://stockhub.co/research/Shield_Therapeutics_plc"